The function of the thyroid gland in patients with multi-drug resistant tuberculosis

Abstract

BackgroundMultidrug-resistant tuberculosis (MDRTB) remains a health problem for many countries in the world. The share of MDRTB is 10–30% among newly diagnosed cases and 20–70% among relapses and treatment failure. The aim of the study is to define the side effects of second line drugs used in the treatment of MDRTB on thyroid function.MethodsIn 30 patients with multidrug resistant tuberculosis, echostructure of thyroid was studied by ultrasound imaging method. Indices of thyroid function: plasma levels of free thyroxin, thyroid stimulating hormone were studied before chemotherapy initiated, at the end of intensive phase and after the treatment finished.ResultsDecreasing of thyroid function under antituberculosis chemotherapy was approved. Monitoring and correction of thyroid function during antituberculosis chemotherapy was suggested.ConclusionPatients with MDRTB taking ethionamide and PAS are at increased risk for hypothyroidism and goiter, and therefore require monitoring of thyroid function at all stages of antituberculosis chemotherapy for its timely correction.

Influence of compensation of selenium deficiency on immunological parameters of patients with multidrugresistant tuberculosis at the background of subclinical hypothyroidism

“…At the same time, in the comparison group, the average level of free thyroxine significantly decreased, and the average level of thyroid-stimulating hormone significantly increased by the end of the intensive therapy phase. The results obtained indicate a negative effect of second-line anti-tuberculosis drugs (ethionamide, prothionamide and PAS and others) on thyroid function, which was observed in other studies [13]. This fact necessitates timely screening of thyroid function during the treatment of drug-resistant tuberculosis.…”

Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis

“…Studies included in this review were reported from 19 countries which cover three continents (Africa, Asia and Europe) [Table 1]. Seventeen studies were reported from Asian [32,34–40,42–44,46,48,53,54,60,61], eight from African [41,45,47,49,50,55,57,58] and five from European [33,48,52,56,59] countries. We categorized Russia, Turkey and Ukraine under European countries category.…”

“…Twenty four studies were based on health facility (hospital, TB clinic, research center and MDR-TB treatment center), while six were community based [Table 1]. In terms of study design, 15 were retrospective cohort study, 13 prospective cohort study, one ambispective cohort study [61] and one study [48] has not reported the study design [Table 1].…”

“…Six studies [32,36,37,39,51,54] used immunoassay based techniques as the method to measure TSH concentration, while 14 studies [38,41,42,44,46,47,49,55–61] retrieved the value of TSH concentration from record (treatment card or laboratory report). However, ten studies [33–35,40,43,45,48,50,52,53] did not report how TSH concentration was measured, and from where data on TSH concentration was collected.…”